Navigation Links
PROLOR Biotech Announces Sale of $24.4 Million of Common Stock
Date:3/18/2010

Jefferies & Company, Inc. served as Lead Placement Agent on the transaction.  Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE  LTS), served as co-placement agent.  

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, biobetter, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins and PROLOR is currently developing long-acting versions of human growth hormone, which is in clinical development, and interferon beta, factor VII, factor IX and erythropoietin, which are in preclinical development, as well as GLP-1 and other therapeutic peptides.  For more information on PROLOR, visit www.prolor-biotech.com.

Safe Harbor Statement:  This press release con
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Biotech Finishes on a High in August, Burrill Report Says
3. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
4. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
5. Biotech delists shares from TSXV, continues OTCBB trading
6. Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007
7. MichBio Announces Formation of Biotechnology Legislative Caucus
8. Oncolytics Biotech Inc. announces approval for UK clinical trial
9. Not just humans benefit from animal biotechnology
10. Biotech adds Central American markets to Sucanon distribution
11. GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 According to a ... "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, Pain Management, ... Microwave, Cryotherapy) - Global Industry Analysis, Size, Share, ... global ablation technologies market was valued at USD ... reach a market worth USD 10,611 million in ...
(Date:8/27/2014)... State University,s Center for Leadership in Disability (CLD) ... Maternal and Child Health Bureau of the Health ... the Autism Plan for Georgia, aimed at improving ... disorder. , In preparing for this project, CLD ... key stakeholders from across Georgia. The resulting plan ...
(Date:8/27/2014)... Representatives with Recharge Retreats ... list of destinations for International Yoga Teacher Trainings. , ... that the company chose Italy due to the fact ... trainings since it's an easy flight for Canadians and ... from all over Europe, UK, Africa, and the Middle ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Maleic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 IQ ... supplements, today announced its continued support of the Cystic ... Formulations participated in a fundraising campaign led by TigerFitness.com ... of IQ Formulations’ sales were donated to the respected ... to a TigerFitness.com fundraiser to support Isla, a young ...
Breaking Medicine News(10 mins):Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2
... On Thursday, January 8, Rhode Island Hospital treated ... as NanoKnife. Damian Dupuy, MD, director of ablation services ... ablation treatment, performed the procedure -- the first time ... the United States. , NanoKnife is an image-guided device ...
... Protica, Inc., the makers of the first capsulized ... to its product line. Following the FDA approval ... made with the natural sweetener will hit the ... the compact 2.9 fluid ounce beverage utilizes Actinase(R). ...
... Ill. and BATESVILLE, Ind., Jan. 9 ,Recognizing the ... excellent care at the patient,s bedside, Joint Commission,Resources ... are collaborating to launch a Nurse,Safety Scholar-in-Residence program ... Joint Commission. Hill-Rom is a global medical technology ...
... perception, reality , , FRIDAY, Jan. 9 (HealthDay News) -- ... their child,s eating and exercise habits, a new study ... Journal of Nutrition Education and Behavior that ... exercised well, while those with older children did not. ...
... Two words strike fear in the hearts of men and ... through the shock of that diagnosis, suffered the grief and ... the opportunity of a lifetime. In his new book, "Life ... AuthorHouse -- http://www.authorhouse.com ), he provides a valuable roadmap ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions ... benefit to the agricultural and consumer,market, announced today that ... January 7, 2009 related to a proposed transaction with ... the outstanding shares,of the Seller. , ...
Cached Medicine News:Health News:Rhode Island Hospital first in US to treat kidney tumor with new device using electrical pulses 2Health News:Protica Launches All-Natural Protein Beverage, Proasis 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Mach One Corporation Enters Letter of Intent to Acquire Ceres Organic Harvest, Inc. 2
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014  As ... is pleased to announce the addition of new ... Center. The Medical Devices Knowledge Center ... research in the healthcare industry. Users have access ... expert, Kalorama Information, published from 1998 to present ...
(Date:8/26/2014)... Scientific Corporation (Nasdaq: KEQU ) today reported ... Sales for the quarter were $30,534,000, as ... last year. Net earnings for the quarter were $1,234,000, ... earnings of $1,587,000, or $0.61 per diluted share, in ... sales and earnings in the first quarter last year ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: